Evidence Hub

Bone mineral density in rheumatoid arthritis patients on antirheumatic therapies: a systematic review

Owen Taylor-Williams, R. Godwin, Reece Carvallio, Michaela Taylor-Williams, Christina Barrett, C. Inderjeeth

Bone, 2026

1 citation

Abstract

Rheumatoid Arthritis (RA) is associated with increased fracture risk due to systemic bone loss. Whilst new disease modifying antirheumatic drugs (DMARD) have improved disease control, their impacts on bone mineral density (BMD) remains controversial. This systematic review investigates the effects of conventional synthetic (cs), biologic (b), and targeted synthetic (ts) DMARDs on BMD in RA patients. 13,340 records were screened, with 46 studies meeting the inclusion and exclusion criteria, published on PROSPERO (CRD42024534452). Included studies were analysed by their use of specific DMARD, glucocorticosteroids (GCS), antiosteoporotic therapy (AOT) and disease activity. csDMARD appear beneficial to BMD, and on the balance of evidence bDMARD and tsDMARD appear to have a greater effect on BMD. Encouragingly, early data suggests some csDMARD, bDMARD, tsDMARD may be superior to others, however, further research is required to confirm this. Future researchers should consider DMARD mechanism of action on BMD and examine the role of specific csDMARD, bDMARD, and tsDMARD in large cohort studies and trials.

How strong is the evidence?

Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free